Alvotech (NASDAQ:ALVOW) Short Interest Update

Alvotech (NASDAQ:ALVOW) was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 600 shares, a decrease of 45.5% from the January 31st total of 1,100 shares. Based on an average daily trading volume, of 8,300 shares, the short-interest ratio is presently 0.1 days.

Alvotech Trading Down 5.4 %

ALVOW stock opened at $2.26 on Friday. The firm has a 50-day moving average of $2.78 and a two-hundred day moving average of $2.83. Alvotech has a 12 month low of $1.71 and a 12 month high of $5.00.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.